These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255 [TBL] [Abstract][Full Text] [Related]
6. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism. Saito S; Ando K; Sakamoto S; Xu M; Yamada Y; Rii J; Kanaoka S; Wei J; Zhao X; Pae S; Kanesaka M; Goto Y; Sazuka T; Imamura Y; Reien Y; Hamaguchi-Suzuki N; Saito S; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N Cancer Sci; 2024 Jul; 115(7):2461-2472. PubMed ID: 38655663 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173 [TBL] [Abstract][Full Text] [Related]
8. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells. Yamaga T; Suehiro J; Wada Y; Sakurai H Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465 [TBL] [Abstract][Full Text] [Related]
9. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549 [TBL] [Abstract][Full Text] [Related]
10. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218 [TBL] [Abstract][Full Text] [Related]
11. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461 [TBL] [Abstract][Full Text] [Related]
12. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742 [TBL] [Abstract][Full Text] [Related]
13. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells. Liu YH; Li YL; Shen HT; Chien PJ; Sheu GT; Wang BY; Chang WW Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681614 [TBL] [Abstract][Full Text] [Related]
14. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203. Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789 [TBL] [Abstract][Full Text] [Related]
15. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells. Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Higuchi K; Sakamoto S; Ando K; Maimaiti M; Takeshita N; Okunushi K; Reien Y; Imamura Y; Sazuka T; Nakamura K; Matsushima J; Furihata T; Ikehara Y; Ichikawa T; Anzai N Sci Rep; 2019 Nov; 9(1):16776. PubMed ID: 31748583 [TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1. Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917 [TBL] [Abstract][Full Text] [Related]
18. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis. Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891 [TBL] [Abstract][Full Text] [Related]
19. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. Toyoshima J; Kusuhara H; Wempe MF; Endou H; Sugiyama Y J Pharm Sci; 2013 Sep; 102(9):3228-38. PubMed ID: 23712732 [TBL] [Abstract][Full Text] [Related]
20. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence. Bo T; Kobayashi S; Inanami O; Fujii J; Nakajima O; Ito T; Yasui H Transl Oncol; 2021 Nov; 14(11):101212. PubMed ID: 34461558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]